AstraZeneca Media Centre have reported that Seven pharmaceutical companies and four research institutions, working with the Bill & Melinda Gates Foundation, have launched a groundbreaking partnership that aims to speed up the discovery of new treatments for TB
The partnership, known as the TB Drug Accelerator (TBDA), will target the discovery of new TB drugs by collaborating on early-stage research. The long-term goal of the TBDA is to create a TB drug regimen that cures patients in only one month. TBDA is aided by nearly $20 million from the Gates Foundation, partners officially launched the TBDA in April and have begun the first round of screening for new TB drug candidates.
“The TB Drug Accelerator establishes a new paradigm of cooperation in drug discovery,” said Sanofi Chief Executive Officer Chris Viehbacher, speaking on behalf of the pharmaceutical industry partners. “By working together on this, we can optimize our research and speed the development of one of the most pressing needs in global health.”
Are you looking for a new clinical job? Click here to see our latest clinical jobs
Follow us on Twitter @CKClinical to receive more industry news and CK jobs of the week updates